Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Go back to Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults| (NASDAQ: AXSM) | Delayed: 209.51 -4.77 (2.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $214.28 | 52 Week High | $15.74 | |||
| Open | $212.05 | 52 Week Low | $5.37 | |||
| Day High | $213.27 | P/E | N/A | |||
| Day Low | $208.28 | EPS | $0.00 | |||
| Volume | 213,479 | |||||
